Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Personal Author:
Duffy, Jonathan ; Marquez, Paige ; Moro, Pedro ; Weintraub, Eric ; Yu, Yon ; ... More +
Duffy, Jonathan ; Marquez, Paige ; Moro, Pedro ; Weintraub, Eric ; Yu, Yon ; Boersma, Peter ; Donahue, James G. ; Glanz, Jason M. ; Goddard, Kristin ; Hambidge, Simon J. ; Lewin, Bruno ; Lewis, Ned ; Rouse, Douglas ; Shimabukuro, Tom Less -
Description:
JYNNEOS (Modified Vaccinia Ankara vaccine, Bavarian Nordic) is recommended in the United States for persons exposed to or at high risk for exposure to Monkeypox virus during the 2022 monkeypox (mpox) outbreak (1). JYNNEOS is a live, nonreplicating viral vaccine licensed for the prevention of smallpox and mpox in adults aged ≥18 years, administered as a 0.5-mL 2-dose series given 28 days apart by subcutaneous injection (2). On August 9, 2022, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for administration of 0.1 mL doses by intradermal injection for adults aged ≥18 years as a strategy to increase vaccine supply, and administration of 0.5 mL doses subcutaneously for persons aged <18 years (3). During May 22-October 21, 2022, a total of 987,294 JYNNEOS vaccine doses were administered in the United States. CDC has monitored JYNNEOS vaccine safety using the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) for vaccine recipients of all ages, and through single-patient emergency Investigational New Drug (EIND) procedures for persons aged <18 years vaccinated before August 9, 2022. The most common adverse health events reported to VAERS for adults were nonserious and included injection site reactions, which was consistent with the prelicensure studies. Adverse health events were reported at similar rates for doses received by intradermal and subcutaneous administration. Serious adverse events were rare in adults, and no serious adverse events have been identified among persons aged <18 years. Overall, postlicensure and postauthorization surveillance to date support JYNNEOS vaccine safety.
Subjects:
[+]
Adolescent Adult Humans Vaccines
Source:
MMWR Morb Mortal Wkly Rep. 71(49):1555-1559
Pubmed ID:
36480476
Pubmed Central ID:
PMC9762898
Document Type:
Journal Article
Name as Subject:
JYNNEOS vaccine
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:80526b2a364d270d6dc1a90777fb7f237985c6508d8477a174a6c4146465365f
Download URL:
https://stacks.cdc.gov/view/cdc/123167/cdc_123167_DS1.pdf
File Type:

Supporting Files

• mm7149a4.nxml

  xml

More +